Currently, multi-drug resistance (MDR) to anticancer drugs is a major obstacle to successful treatment of cancer. Looking for novel compounds with anti-MDR activity is an effectively way to overcome cancer drug resistance. Here, we found that H1, a novel derivate of Tetrandrine, displayed anti-MDR activity in vitro and in vivo. Average resistant factor of H1 is only 1.6. In KB and KBv200 cancer cells xenograft mice, H1 also displayed favorable anti-MDR activity. It could induce typical apoptosis as indicated by morphologic changes, DNA fragmentation in sensitive and resistant cancer cells. Further studies showed that H1 treatment resulted in the increase of ROS generation, elevation of the Bax/Bcl-2 ratio, loss of mitochondrial transmembrane potential (ΔΨ(m)), release of cytochrome c and AIF from mitochondria into cytosol, and activation of caspase-9 and caspase-3, but had no effect on activation of caspase-8 and the expression of Fas/FasL. On the other hand, H1 also inhibited survival pathways such as the activation of Erk1/2 and Akt1/2. In conclusion, H1 exerts good anti-MDR activity in vitro and in vivo, its mechanisms may be associated with initiating intrinsic apoptosis pathway and inhibiting the activation of Erk1/2 and Akt1/2. These findings further support the potential of H1 to be used in clinical trial of MDR cancer treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bcp.2011.08.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design, synthesis and biological evaluation of novel diaryl-substituted fused nitrogen heterocycles as tubulin polymerization inhibitors to overcome multidrug resistance in vitro and in vivo.
Eur J Med Chem
February 2025
School of Pharmacy, Fudan University, Shanghai, 201203, China; School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, 453007, China. Electronic address:
Article Synopsis
- * A new compound, benzoimidazole derivative 37, shows strong cytotoxic effects and can overcome MDR in resistant A549 cells by disrupting microtubule assembly and reducing P-glycoprotein levels.
- * In vivo tests indicate that compound 37 inhibits tumor growth effectively with low toxicity, making it a promising candidate for treating multidrug-resistant LUAD in future clinical applications.
Maydisens, Sesterterpenoids with Anti-MDR Activity from .
J Nat Prod
October 2024
Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, People's Republic of China.
Fourteen previously undescribed sesterterpenoids (-) were isolated from . Their structures with absolute configurations were elucidated by NMR, HRESIMS, DP4+ calculations, ECD calculations, single-crystal X-ray diffraction analyses, and the modified Mosher's method. Compounds - possess an uncommon 5/11 bicyclic ring system identified from for the first time.
View Article and Find Full Text PDFLansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration.
Drug Resist Updat
September 2024
Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin 300060, China; Tianjin Medical University, Tianjin 300070, China; Key Laboratory of Immune Microenvironment and Diseases (Ministry of Education), Tianjin Medical University, Tianjin 300070, China. Electronic address:
Aims: Lansoprazole is one of the many proton pump inhibitors (PPIs) that acts more strongly with ABCB1 and ABCG2. The present study is to investigate the potential of lansoprazole on reversal of ABCB1/G2-mediated MDR in cancer, in vitro and in vivo.
Methods: Reversal studies and combination evaluation were conducted to determine the synergistic anti-MDR effects on lansoprazole.
Schematic-portfolio of potent anti-microbial scaffolds targeting DNA gyrase: Unlocking ways to overcome resistance.
Int J Biol Macromol
January 2024
Medicinal Chemistry Research Laboratory, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan Deemed to be University, Bhubaneswar 751003, Odisha, India. Electronic address:
Drug development process demands validation of specific drug target impeding the Multi Drug Resistance (MDR). DNA gyrase, as a bacterial target has been in trend for developing newer antibacterial candidates due to its absence in higher eukaryotes. The fluoroquinolones are the leading molecules in the drug discovery pipeline for gyrase inhibition due to its diversity.
View Article and Find Full Text PDFRecent advance on nanoparticles or nanomaterials with anti-multidrug resistant bacteria and anti-bacterial biofilm properties: A systematic review.
Heliyon
November 2023
Student Research Committee, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Article Synopsis
- Objective: Researchers are tackling the issue of multidrug-resistant bacteria (MDR) by exploring the use of antibacterial nanomaterials to combat infections caused by these resistant pathogens.
- Methods: The study reviews research from various biomedical databases, analyzing 41 studies on the antibacterial and anti-biofilm properties of different nanomaterials published from 2007 to December 2022.
- Results: Nineteen types of nanomaterials showed potential antibacterial properties, while seven were identified as agents against biofilms, suggesting that these materials could be crucial in developing new treatments to combat antibiotic resistance and prevent disease outbreaks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!